# Illumina, Inc. (ILMN) stock news and updates

As of October 29, 2026. Source: https://www.clearthesis.ai/updates/ILMN

## Our view on the Illumina, Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/ILMN

## Latest updates on Illumina, Inc.

### Illumina beats expectations and raises its full-year outlook

*October 29, 2026 · earnings · significance: major · signal: positive*

Illumina reported earnings of $1.62 per share, well above the $1.36 analysts were expecting. Revenue reached $1.17 billion, also topping estimates, as the company saw healthy demand for its genetic sequencing machines and the chemical kits used to run them. Management noted that placements of its newest high-end platform, the NovaSeq X, are ahead of schedule. Following the strong quarter, the company raised its financial targets for the full year. This is a positive sign for the business as it refocuses on its core sequencing technology after spinning off its cancer-testing unit, GRAIL. The growth in clinical demand suggests that genetic testing is becoming more routine in healthcare, which helps protect Illumina's long-term revenue.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1110803/000111080326000202/0001110803-26-000202-index.htm)

### New BioInsight software launched to simplify genetic data analysis

*October 29, 2026 · product · significance: notable · signal: positive*

Illumina launched BioInsight, a new software environment designed to handle the massive amounts of data produced by its sequencing machines. The platform uses artificial intelligence to help scientists identify biological patterns more quickly, which is a key part of making genetic research more efficient. This move is important because it strengthens Illumina's "razor and blade" business model. By providing better software to analyze the data, Illumina makes its hardware more useful and keeps customers locked into its ecosystem. It also includes an update to its DRAGEN analysis tool, which helps labs process data more accurately.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/illumina-launches-bioinsight-platform-its-first-unified-software-environment-to-help-accelerate-genomic-and-multiomic-breakthroughs-302907972.html)

### Updated AI model released to help identify rare disease variants

*October 29, 2026 · product · significance: minor · signal: positive*

Illumina introduced SpliceAI2, an updated artificial intelligence tool designed to help researchers understand how genetic changes affect the body. In early tests, the model identified 17 percent more variants related to rare diseases compared to older methods. While this is a specialized tool, it helps maintain Illumina's position as the primary technology provider for genetic research labs.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/illumina-releases-spliceai2-to-help-advance-rare-disease-research-302902489.html)

### Illumina sets up a $1 billion short-term borrowing program

*October 29, 2026 · filing · significance: minor · signal: neutral*

On October 8, Illumina entered into agreements to create a commercial paper program, which allows it to issue short-term, unsecured debt. The company can have up to $1 billion in these notes outstanding at any time, with the money intended for general corporate purposes. This is a routine financial move that gives the company more flexibility to manage its daily cash needs and expenses.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1110803/000111080326000195/0001110803-26-000195-index.htm)

### Canaccord Genuity raised its target to $300

*October 29, 2026 · analyst · significance: minor · signal: neutral*

Canaccord Genuity raised its price target for Illumina to $300 from $205 but kept its rating at Hold. This means the firm thinks the stock is fairly valued at its current price rather than being a clear buy. The new target is slightly above the current average of $253 across all analysts who follow the company.

Sources: [Canaccord Genuity](https://thefly.com/ajax/news_get.php?id=4443932)

## Illumina, Inc. earnings

In Q3 2026, reported on October 29, 2026, Illumina, Inc. posted earnings of $1.62 per share against $1.36 expected, and revenue of $1.2 billion against $1.2 billion expected.

The next earnings report is expected on October 29, 2026. Analysts expect $1.36 per share. Revenue is expected around $1.2 billion.

What to watch: We are watching consumable revenue growth, which measures the sales of chemical kits used for every test and shows how much customers are actually using their machines.

## Recent analyst activity on ILMN

- October 23, 2026: Stephens Set target. Price target: $275.00.
- October 19, 2026: Canaccord Genuity Kept rating at Hold, raised target from $205. Price target: $300.00.
- October 13, 2026: TD Cowen Kept rating at Hold.
- October 7, 2026: Barclays Kept rating at Underweight, raised target from $160. Price target: $200.00.
- October 5, 2026: RBC Capital Kept rating at Outperform.
- October 1, 2026: Guggenheim Kept rating at Buy, raised target from $226. Price target: $305.00.

## What's ahead for Illumina, Inc.

- October 29, 2026: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/ILMN
